TCRX
HEALTHCARETscan Therapeutics Inc
AI Insight
What's Moving TCRX Today?
No stock-specific AI insight has been generated for TCRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.85$2.57
$0.91
Fundamentals
Market Cap$61M
P/E Ratio—
EPS$-0.96
Dividend Yield—
Dividend / Share—
ROE-80.9%
Profit Margin—
Debt / Equity—
Trading
Volume95K
Avg Volume (10D)—
Shares Outstanding61.1M
TCRX News
20 articles- TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceYahoo Finance·Jun 24, 2026
- TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationYahoo Finance·Jun 22, 2026
- Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesYahoo Finance·Jun 3, 2026
- TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net LossYahoo Finance·Jun 2, 2026
- TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 6, 2026
- TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingYahoo Finance·Apr 27, 2026
- TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc.·Apr 8, 2026
- Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceYahoo Finance·Mar 25, 2026
- TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 4, 2026
- TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 4, 2026
- TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03Yahoo Finance·Feb 26, 2026
- Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 25, 2026
- TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 12, 2026
- Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?Yahoo Finance·Feb 11, 2026
- Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Feb 6, 2026
- TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and ExpositionYahoo Finance·Dec 6, 2025
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market OpportunitiesYahoo Finance·Dec 3, 2025
- TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 12, 2025
All 20 articles loaded
Price Data
Open$0.93
Previous Close$0.92
Day High$0.95
Day Low$0.91
52 Week High$2.57
52 Week Low$0.85
52-Week Range
$0.85$2.57
$0.91
Fundamentals
Market Cap$61M
P/E Ratio—
EPS$-0.96
Dividend Yield—
Dividend / Share—
ROE-80.9%
Profit Margin—
Debt / Equity—
Trading
Volume95K
Avg Volume (10D)—
Shares Outstanding61.1M
About Tscan Therapeutics Inc
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company at the forefront of precision cancer treatment, utilizing its innovative T cell receptor (TCR) discovery platform to specifically target cancer antigens. Committed to advancing TCR-based therapeutics, Tscan is actively developing a diverse pipeline aimed at addressing various malignancies and improving patient outcomes. The company's robust intellectual property portfolio and strategic focus position it favorably within the rapidly evolving T cell-based immunotherapy landscape, addressing critical unmet medical needs in oncology.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—